Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

ICEMAN (Intelligent Choice of Excision Margin): A Randomized Controlled Trial of Narrow Excision Versus Wide Excision for Adults With Primary Invasive Cutaneous Melanomas

NCT06673095 is registered in ClinicalTrials.gov with OHSU Knight Cancer Institute as lead sponsor.

NCT NCT06673095
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06673095 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
ICEMAN (Intelligent Choice of Excision Margin): A Randomized Controlled Trial of Narrow Excision Versus Wide Excision for Adults With Primary Invasive Cutaneous Melanomas
Lead sponsor
OHSU Knight Cancer Institute
Phase
Not applicable
Overall status
Recruiting
Start date
December 11, 2024
Completion date
December 31, 2027
Enrollment
1,000 (estimated)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

clinical stage ia cutaneous melanoma ajcc v8, clinical stage ib cutaneous melanoma ajcc v8